SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Detection of NAFLD, and associated fibrosis, will facilitate enrolment in relevant clinical trials, and may encourage prescription of glucose-lowering therapies that target steatosis, steatohepatitis, or even fibrosis (including DDP-4 inhibitors, GLP receptor agonists and SGLT2 inhibitors) [45].